Finlay, J., Mynarek, M., Dhall, G., Mazewski, C., Grundy, R., Cohen, B. H., … Rutkowski, S. (2020). MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING – A COMPARATIVE OUTCOMES ANALYSIS. In Neuro-Oncology (Vol. 22, pp. iii396–iii397). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noaa222.513

Finlay, Jonathan, Martin Mynarek, Girish Dhall, Claire Mazewski, Richard Grundy, Bruce H. Cohen, Giles Robinson, et al. “MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING – A COMPARATIVE OUTCOMES ANALYSIS.” In Neuro-Oncology, 22:iii396–97. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa222.513.

Finlay J, Mynarek M, Dhall G, Mazewski C, Grundy R, Cohen BH, et al. MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING – A COMPARATIVE OUTCOMES ANALYSIS. In: Neuro-Oncology. Oxford University Press (OUP); 2020. p. iii396–7.

Finlay, Jonathan, et al. “MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING – A COMPARATIVE OUTCOMES ANALYSIS.” Neuro-Oncology, vol. 22, no. Supplement_3, Oxford University Press (OUP), 2020, pp. iii396–97. Crossref, doi:10.1093/neuonc/noaa222.513.

Finlay J, Mynarek M, Dhall G, Mazewski C, Grundy R, Cohen BH, Robinson G, Ashley D, Stanek JR, Gajjar A, Rutkowski S. MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING – A COMPARATIVE OUTCOMES ANALYSIS. Neuro-Oncology. Oxford University Press (OUP); 2020. p. iii396–iii397.